Michael Kaseta Sells 36,932 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 36,932 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the completion of the sale, the chief financial officer owned 350,919 shares in the company, valued at $13,134,898.17. This represents a 9.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 1st, Michael Kaseta sold 1,166 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $37,533.54.

Liquidia Trading Up 5.0%

Shares of LQDA stock opened at $39.99 on Thursday. The company has a market capitalization of $3.48 billion, a P/E ratio of -27.77, a P/E/G ratio of 0.65 and a beta of 0.48. Liquidia Corporation has a 12-month low of $11.26 and a 12-month high of $40.53. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The firm has a 50-day moving average price of $32.41 and a 200 day moving average price of $25.68.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. The firm’s quarterly revenue was up 1106.7% compared to the same quarter last year. Research analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LQDA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Needham & Company LLC upped their price target on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Wells Fargo & Company assumed coverage on shares of Liquidia in a research note on Monday, October 20th. They issued an “overweight” rating and a $31.00 target price for the company. Finally, HC Wainwright upped their target price on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after buying an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the last quarter. Rhumbline Advisers grew its holdings in Liquidia by 6.0% during the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock worth $1,261,000 after acquiring an additional 4,811 shares during the period. Finally, Ballentine Partners LLC raised its position in shares of Liquidia by 10.2% during the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock valued at $151,000 after acquiring an additional 1,119 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).